Suppr超能文献

持续性非卧床腹膜透析患者的普鲁卡因胺药代动力学

Procainamide pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.

作者信息

Raehl C L, Moorthy A V, Beirne G J

出版信息

Nephron. 1986;44(3):191-4. doi: 10.1159/000183984.

Abstract

The pharmacokinetics of procainamide in patients on continuous ambulatory peritoneal dialysis have been studied. A mean peak plasma concentration of 3.2 +/- 0.6 microgram/ml was achieved about 2 h after a single 500-mg oral procainamide hydrochloride dose. The procainamide elimination half-life ranged from 6.1 to 15.3 h. Apparent oral clearance, 183.7 +/- 63.2 ml/min, was less than half that observed in healthy adults suggesting markedly reduced dosage requirements. Continuous ambulatory dialysis patients exhibit similar procainamide pharmacokinetic parameters as do end stage renal disease patients, most notably a prolonged elimination half-life and reduced oral clearance.

摘要

已对持续性非卧床腹膜透析患者中普鲁卡因胺的药代动力学进行了研究。单次口服500毫克盐酸普鲁卡因胺后约2小时,平均血浆峰浓度达到3.2±0.6微克/毫升。普鲁卡因胺的消除半衰期为6.1至15.3小时。表观口服清除率为183.7±63.2毫升/分钟,不到健康成年人的一半,提示所需剂量明显减少。持续性非卧床透析患者的普鲁卡因胺药代动力学参数与终末期肾病患者相似,最显著的是消除半衰期延长和口服清除率降低。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验